The spectrum of GATA2 deficiency syndrome

• Published in: Blood 2023-03, Vol.141 (13), p.1524-1532
• Main Authors: Calvo, Katherine R., Hickstein, Dennis D.
• Format: Article
• Language: English
• Subjects: GATA2 Deficiency - complications; GATA2 Deficiency - genetics; GATA2 Deficiency - therapy; GATA2 Transcription Factor - genetics; Germ-Line Mutation; Humans; Mutation; Myelodysplastic Syndromes - genetics; Myelodysplastic Syndromes - pathology; Myelodysplastic Syndromes - therapy; Myeloproliferative Disorders
• ISSN: 0006-4971; 1528-0020; 1528-0020
• DOI: 10.1182/blood.2022017764

[Display omitted] Inherited or de novo germ line heterozygous mutations in the gene encoding the transcription factor GATA2 lead to its deficiency. This results in a constellation of clinical features including nontuberculous mycobacterial, bacterial, fungal, and human papillomavirus infections, lymphedema, pulmonary alveolar proteinosis, and myelodysplasia. The onset, or even the presence, of disease is highly variable, even in kindreds with the identical mutation in GATA2. The clinical manifestations result from the loss of a multilineage progenitor that gives rise to B lymphocytes, monocytes, natural killer cells, and dendritic cells, leading to cytopenias of these lineages and subsequent infections. The bone marrow failure is typically characterized by hypocellularity. Dysplasia may either be absent or subtle but typically evolves into multilineage dysplasia with prominent dysmegakaryopoiesis, followed in some instances by progression to myeloid malignancies, specifically myelodysplastic syndrome, acute myelogenous leukemia, and chronic myelomonocytic leukemia. The latter 3 malignancies often occur in the setting of monosomy 7, trisomy 8, and acquired mutations in ASXL1 or in STAG2. Importantly, myeloid malignancy may represent the primary presentation of disease without recognition of other syndromic features. Allogeneic hematopoietic stem cell transplantation (HSCT) results in reversal of the phenotype. There remain important unanswered questions in GATA2 deficiency, including the following: (1) Why do some family members remain asymptomatic despite harboring deleterious mutations in GATA2? (2) What are the genetic changes that lead to myeloid progression? (3) What causes the apparent genetic anticipation? (4) What is the role of preemptive HSCT? Routine use of next-generation sequencing of hematologic malignancies has greatly expanded the representation of hereditary predisposition syndromes among patients with leukemia. Introduced by Associate Editor Mario Cazzola, this Review Series highlights 4 such genetic predisposition syndromes and provides strong support for the need to include germ line genetic testing for patients with myelodysplasia and myeloid leukemia.